Maravai LifeSciences Target of Unusually Large Options Trading (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the target of some unusual options trading on Wednesday. Stock investors purchased 1,002 put options on the stock. This represents an increase of 1,791% compared to the average volume of 53 put options.

Maravai LifeSciences Stock Performance

Shares of NASDAQ:MRVI opened at $1.96 on Friday. The firm has a market capitalization of $498.50 million, a PE ratio of -1.20 and a beta of 0.19. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. The business has a 50-day moving average of $2.11 and a two-hundred day moving average of $4.09. Maravai LifeSciences has a 12 month low of $1.67 and a 12 month high of $11.56.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $46.85 million for the quarter, compared to analyst estimates of $44.01 million. Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. The business’s revenue was down 26.9% compared to the same quarter last year. As a group, research analysts forecast that Maravai LifeSciences will post -0.24 earnings per share for the current year.

Analysts Set New Price Targets

MRVI has been the topic of several recent research reports. Bank of America reduced their price objective on Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Robert W. Baird reduced their target price on Maravai LifeSciences from $3.00 to $2.00 and set a “neutral” rating on the stock in a research report on Tuesday. Stifel Nicolaus set a $5.00 target price on Maravai LifeSciences in a research report on Friday, March 21st. UBS Group reduced their target price on Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating on the stock in a research report on Friday, March 21st. Finally, Craig Hallum reduced their target price on Maravai LifeSciences from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $6.64.

Institutional Investors Weigh In On Maravai LifeSciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Immersion Corp acquired a new stake in Maravai LifeSciences during the first quarter worth about $864,000. Vident Advisory LLC grew its stake in shares of Maravai LifeSciences by 289.5% in the first quarter. Vident Advisory LLC now owns 110,567 shares of the company’s stock valued at $244,000 after buying an additional 82,182 shares in the last quarter. Delta Investment Management LLC grew its stake in shares of Maravai LifeSciences by 33.2% in the first quarter. Delta Investment Management LLC now owns 443,689 shares of the company’s stock valued at $981,000 after buying an additional 110,696 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of Maravai LifeSciences in the first quarter valued at about $511,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Maravai LifeSciences in the first quarter valued at about $32,000. 50.25% of the stock is currently owned by institutional investors and hedge funds.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.